Octreotide Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Expanding Use in Neuroendocrine Tumors: Octreotide as the Backbone of Combination Regimens

Gastroenteropancreatic neuroendocrine tumor incidence in the United States reached 6.1 cases per 100,000 people, while the 20-year limited-duration prevalence totaled 248,546 cases as of January 1, 2021. This expanding patient base supports recurring demand in the octreotide market, as treatment often continues over extended periods. The PROMID study reported median progression-free survival of 14.3 months with octreotide long-acting release (LAR), compared with 6.0 months with placebo, supporting its antiproliferative use in appropriate patients.^[2] The European Society for Medical Oncology continues to recognize somatostatin analog therapy in its guidance for neuroendocrine and endocrine tumors. Octreotide also supports radioligand therapy regimens, with NETTER-2 reporting progression-free survival of 23.0 months for lutetium-177 dotatate plus octreotide, compared with 8.5 months for octreotide alone. Wider radioligand therapy availability at specialist centers may further support demand among patients with higher disease burden. Coordinated oncology and endocrinology care, including imaging, biochemical assessment, and treatment reviews, reinforces demand for established therapies and continuity of treatment.

Persistent Demand for Acromegaly Maintenance Therapy: Injectable SSAs Retain the Hardest-to-Treat Cohort

Acromegaly requires long-term biochemical monitoring and continued treatment for many patients. Debiopharm reported that up to 77% of patients receiving standard monthly somatostatin analog regimens experienced injection-site adverse events. However, the need to maintain biochemical control makes treatment interruption difficult despite the burden of regular injections. This supports demand for established injectable therapies among responsive patients and creates opportunities for formulations that reduce administration frequency. Paltusotine received Food and Drug Administration (FDA) approval in September 2025 as a once-daily oral, non-peptide somatostatin receptor subtype 2 agonist for adults with acromegaly.^[3] Injectable somatostatin analogs remain relevant for patients requiring established maintenance approaches, particularly those with incomplete insulin-like growth factor 1 control who may need treatment escalation. Improved diagnosis in emerging health systems can expand the treated patient pool and support the projected 12.45% growth rate for acromegaly within the octreotide market.

Generic Long-Acting-Release Entry Expanding Treatment Access: The Access-Erosion Paradox

Teva launched the first generic version of Sandostatin LAR Depot in the United States in October 2024. Generic long-acting-release products improve access to complex depot therapies for payers and providers while increasing pressure on branded pricing and formulary positioning. The key market benefit is wider treatment availability in cost-sensitive settings; however, lower revenue per unit offsets commercial gains for manufacturers. This dynamic drives volume growth without comparable revenue growth for the originator brand. Manufacturing remains complex because these products require controlled microsphere performance and proven sterility, release characteristics, and bioequivalence. Limited qualified manufacturing capacity can restrict the number of competing suppliers. Consequently, health plans and providers assess generic products based on pricing and supply continuity, particularly when delayed dosing could disrupt established maintenance schedules.

Oral and Self-Administered Somatostatin-Pathway Innovation: Formulation Pipeline More Active Than at Any Prior Period

Triastek received FDA investigational new drug clearance for T25, an oral octreotide acetate tablet, in April 2026. The product uses a three-dimensional printed tablet design intended to protect the peptide through the digestive tract and enables clinical evaluation in the United States. An oral formulation could reduce dependence on clinic-based intramuscular administration and expand options for patients who find injections difficult. Camurus presented Phase III ACROINNOVA 2 results showing stable insulin-like growth factor 1 control through 52 weeks with its subcutaneous program. The company’s June 2026 presentation stated that the SORENTO study enrolled 332 participants across 103 sites in 12 countries. Self-administered options could shift suitable maintenance patients toward lower-cost care settings and reduce pressure on hospital injection capacity. However, clinic-based therapies remain necessary for complex cases, as these patients require close specialist supervision and regular clinical assessment.

Generic Price Erosion in Long-Acting-Release Products: Revenue Compression Beneath Volume Expansion

Novartis reported USD 1,213 million in 2025 sales for the Sandostatin LAR (long-acting release) group, reflecting a 5% decline at constant currency. Generic entry in the United States remains a key driver of lower realized prices for branded long-acting-release products. This pressure can continue even as patient treatment volumes increase, as payers favor lower-cost alternatives that meet coverage requirements. Consequently, branded revenue can decline despite stable or expanding treatment volumes. Although Sandostatin LAR benefits from established prescribing patterns and specialist familiarity, price differentials can affect hospital purchasing and payer coverage decisions. Manufacturers must strengthen their value proposition through competitive contracting, supply reliability, and clinical administration support.

Buy-and-Bill and Site-of-Care Reimbursement Friction: A Structural Barrier to Clinic-Level Adoption

The buy-and-bill model requires providers to purchase treatment before receiving reimbursement, creating financial pressure for smaller oncology and endocrinology practices when acquisition costs and reimbursement timelines do not align. Larger hospital systems have established billing processes and stronger purchasing capabilities, contributing to their 60.12% share of octreotide market revenue in 2025. These reimbursement dynamics can slow the adoption of newer depot products in smaller care settings and influence treatment administration sites. Specialty clinics remain a growth opportunity, with the segment projected to grow by 11.85% through 2032. Self-administered delivery can reduce practice-based drug purchasing requirements for certain patients, while complex cases continue to require monitoring and coordinated treatment. Clinic growth depends on providers’ ability to manage administration without excessive financial risk.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Octreotide Market Segment Analysis

Generic octreotide is projected to grow at a compound annual growth rate (CAGR) of 12.67% through 2032. Teva’s October 2024 United States launch introduced a generic long-acting release (LAR) option in a category historically led by the originator brand. Generic products can expand treatment access where pricing influences prescribing decisions and coverage. They can also prompt purchasing groups and health plans to reassess preferred-product designations.

Branded octreotide held a 53.45% share of the octreotide market in 2026. Branded products retain advantages through clinical familiarity, established distribution arrangements, and existing treatment protocols. Novartis reported Sandostatin LAR group sales of USD 1,213 million in 2025, confirming the franchise’s continued commercial scale. Generic competition will continue to pressure brand pricing and formulary placement, while suppliers compete on access, pricing, and supply reliability.

Long-acting-release injectable suspension captured 58.56% of formulation revenue in 2026. The format supports regular maintenance treatment for neuroendocrine tumors and acromegaly. Monthly dosing provides clinicians with a familiar approach to monitoring disease control and managing treatment schedules. Established hospital workflows and trained providers continue to support its market position.

Depot microsphere injection is projected to grow at a 11.68% CAGR from 2027 to 2032. The technology requires precise control of polymer properties, drug loading, and release behavior, which can limit new competitor entry. Immediate-release injections continue to address acute-care needs, including esophageal variceal bleeding. Oral candidates, such as T25, represent a separate development pathway, subject to further clinical and regulatory progress.

Intramuscular administration held 54.89% of revenue in 2026. Sandostatin LAR Depot uses an established gluteal intramuscular administration protocol. This route supports scheduled maintenance therapy and remains integrated into current clinical care pathways. Provider familiarity will continue to support its use across hospitals and specialty practices.

Oral and other investigational routes are projected to grow at a 13.34% CAGR through 2032. Subcutaneous approaches may reduce dependence on intramuscular clinic visits for suitable patients, while Camurus reported Phase III evidence of ongoing biochemical control with its subcutaneous program. Triastek’s T25 could further expand oral treatment options. Intravenous and short-acting subcutaneous products will continue to serve acute and outpatient-care needs.

Gastroenteropancreatic neuroendocrine tumors accounted for 58.23% of the octreotide market size in 2026. The indication benefits from established clinical guidance and continued specialist use of somatostatin analogs. United States epidemiology data recorded a 20-year limited-duration prevalence of 248,546 neuroendocrine neoplasm cases in 2021. Combination approaches can further support use in selected advanced cases.

Acromegaly is projected to grow at a 12.45% CAGR through 2032. The indication requires long-term management to maintain biochemical control, supporting demand for injectable somatostatin analogs. The September 2025 approval of paltusotine introduced an oral option for adults with acromegaly. Acute uses, including esophageal variceal bleeding and secretory diarrhea, will continue to support demand for immediate-release products.

Hospitals held 60.12% of the octreotide market share in 2026. They administer acute-use octreotide and long-acting products for patients with complex neuroendocrine and endocrine conditions. Hospitals also maintain the staffing, cold-chain infrastructure, and purchasing systems required for depot injections. Their role remains particularly important in complex oncology care.

Specialty clinics are projected to grow at an 11.85% CAGR through 2032. These settings provide regular care for stable patients with endocrine and oncology conditions, supported by generic availability and lower-burden delivery systems. Self-administered treatment may allow some patients to transition from hospital-centered administration. Endocrinology clinics and oncology centers will continue to play a key role in monitoring symptoms, biochemical response, and patient follow-up.

Geography Analysis

North America

North America is projected to account for a 39.88% share of the octreotide market in 2026. The region benefits from established specialty care infrastructure, broad access to endocrinology and oncology providers, and the long-standing Sandostatin franchise. Teva’s 2024 launch of a generic long-acting release option in the United States is expected to influence purchasing decisions among payers and providers managing high-cost specialty medicines. Hospitals and specialist practices will continue to influence the pace of product switching, while new self-administered approaches may expand the range of care settings over time.

Asia-Pacific

Asia-Pacific is forecast to grow at a compound annual growth rate (CAGR) of 13.77% during 2027-2032. Expanding specialty care capacity and broader treatment access across major health systems will support this growth. Triastek is expected to receive U.S. Food and Drug Administration (FDA) investigational new drug clearance for T25 in April 2026, introducing an oral development pathway that supports the region’s innovation base. Funding levels and diagnostic capacities vary across Asia-Pacific countries; therefore, adoption is unlikely to be uniform. However, improved access to endocrinology and oncology care can support demand over time.

Europe, South America, Middle East, and Africa

Europe remains a major geographic cluster in the octreotide market, with Germany, France, and the United Kingdom serving as key contributors. The region has experienced generic competition in long-acting release products and maintains an established network of specialist centers. Novartis is expected to report continued pressure on Sandostatin long-acting release (LAR) from generic competition in its 2025 annual report. Europe also plays an important role in developing longer-interval products, with Debiopharm expected to initiate the Phase III OXTEND-03 trial across 75 sites in 21 countries in December 2025. South America and the Middle East and Africa offer opportunities to improve patient access as diagnostic capabilities and specialist care expand. Progress in these regions will depend on referral pathways, specialist availability, and reimbursement support.